Routine, Opt-Out Screening for HIV, STDs, Viral Hepatitis, & Tuberculosis in High-Impact Settings

Policymakers and decision-makers have a unique ability to advance health policies in high-impact settings. Policymakers and decision-makers can use this policy toolkit to understand how routine, opt-out screening policies: (a) could benefit their state; (b) have been and can be codified; and (c) are affected by local context.

Routine, opt-out screening occurs when a healthcare provider screens all eligible patients (routine) instead of using an individualized risk-based assessment, and informs the patient that a test will be performed unless they explicitly decline the test (opt-out).

This toolkit of Routine, Opt-Out Screening Policy Snapshots aims to equip policy and decision-makers with actionable steps to advance routine, opt-out screening policy and procedures in high-impact settings, and through population-based services. This toolkit was informed by an assessment of policies related to routine, opt-out screening in six states, which collectively account for a significant percentage of HIV, STD, viral hepatitis, and tuberculosis infections nationwide (California, Florida, Georgia, Illinois, New York, and Texas).

Routine, opt-out screening is a health equity intervention. In high-impact settings, routine, opt-out screening can reduce stigma and misconceptions, detect undiagnosed infections, facilitate linkage to treatment, and reduce risk of transmission.

Click on the icons below to view policy snapshots for each high-impact setting or population-based service.




Harm Reduction &
Syringe Services Programs




School-Based Health


In partnership with CDC and supported by NNPHI, the Research & Evaluation Group at Public Health Management Corporation, an NNPHI member institute, conducted an assessment of state and local screening policies, as well as eight key informant interviews with experts in each high-impact setting and population-based service, to inform their development of this toolkit. Project work began in June 2022 and continues at present.

For more information, please contact us at

Connect with us:

Twitter LinkedIn YouTube
Google Plus email
Connect With Us:
Subscribe To Our Communications